"Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study"
Sponsor study identifier
observational
30
1 country
1
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2006
Actual (reported)Study Completion
Not reported
Date not reportedThe purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to breast cancer. Tartrate-resistant acid phosphatase (TRAP) is a protein released into the blood stream as a result of bone destruction caused by metastasis of breast cancer to the bone. Bone destruction causes pain and bone fractures. This study will measure TRAP levels in serum taken from breast cancer patients to see if TRAP levels will be able to predict the effect of Zometa® treatment on bone destruction, pain and bone fractures.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
December 9, 2005
Actual (reported)December 12, 2005
Actual (reported)May 2006
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
James Graham Brown Cancer Center, 529 S. Jackson St.
Louisville, Kentucky, 40202, United States
Leela Bhupalam, MD
University of Louisville, James Graham Brown Cancer Center
First Submitted
December 9, 2005
First Posted
December 12, 2005
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2006
Actual (reported)Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
Contact the study team to confirm eligibility.
Last Updated
December 29, 2017
Record last verified: 2017-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: